Biotech Explained· @Explainbiotech · X·· 6 小时前评分70
正文 · 原文
Article updated with Day 2 of #ESMO26.
An important day for patients: DeLLphi-305 delivered a major survival benefit in small-cell lung cancer, VOLGA improved survival in operable bladder cancer, and DASL-HiCaP showed progress in preventing prostate cancer metastases.
The key results, the science behind them, and what they could change, all in the updated article below.
$AMGN $AZN $PFE
63 浏览 · 1 赞 · 0 转发 · 0 回复
会议摘要
LBA3按 Presidential Symposium I 对上
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.orgESMO 2026 just started in Madrid, one of the biggest oncology congresses of the year. Schedule of the key presentations + what already came out on Day 1 : full breakdown in the article. https://x.com/i/article/2113769981779357697在 X 查看被引用的帖子
来源：Biotech Explained · x.com